膜杰作
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax
功能细胞系
基于明确MOA设计，便于药物机制研究；
反应信号强，确保高灵敏度；
检测窗口大， 适用不同药效筛选；
代次稳定性好，利于方法学验证；
应用场景明确，方便客户选择；
配套产品供应，实现一站服务。
细胞内信号转导通路研究；
配体受体之间的相互作用；
早期药物筛选和新药研发；
| 货号 | Host cell | 产品描述 | Applications | 订购/预购 |
|---|---|---|---|---|
| CHEK-ATF044 | HEK293 | VEGFR2 (Luc) HEK293 Reporter Cell | Screen for anti-human VEGF or anti-human VEGFR neutralizing antibody | |
| CHEK-ATF045 | HEK293 | TSLPR (Luc) HEK293 Reporter Cell | Screen for anti-human TSLP or anti-human TSLPR neutralizing antibody | |
| CJUR-STF046 | Jurkat | NFAT (Luc) Jurkat Reporter Cell | Screen for T cell activators | |
| CHEK-ATF047 | HEK293 | STAT3 (Luc) HEK293 Reporter Cell | Screen for STAT3 activators or inhibitors | |
| CHEK-ATF048 | HEK293 | NF-κB (Luc) HEK293 Reporter Cell | Screen for NF-kB inhibitors and activators. | |
| CHEK-ATF049 | HEK293 | EGFR (Luc) HEK293 Reporter Cell | Screen for anti-human EGFR or anti-human EGF neutralizing antibody or small molecule inhibitor | |
| CHEK-ATF050 | HEK293 | NFAT (Luc) HEK293 Reporter Cell | Screen NFAT activators or inhibitors |
Co-expression analysis of human TSLPR and IL7Rα on TSLPR (Luc) HEK293 Reporter Cell by FACS. Cell surface staining was performed on TSLPR (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-TSLPR antibody and FITC-labeled anti-IL7Rα antibody.
Protocol
Response to human TSLP protein (RLU). The TSLPR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TSLP protein (AcroBiosystems, Cat.No.TSP-H52Hb). The EC50 was approximately 0.1392 μg/mL.
Protocol
Response to human TSLP protein (Fold). The TSLPR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TSLP protein (AcroBiosystems, Cat.No.TSP-H52Hb). The max induction fold was approximately 45.15.
Protocol
Passage stability analysis of receptors expression by FACS. Flow cytometry surface staining of human TSLPR and IL7Rα on TSLPR (Luc) HEK293 Reporter Cell demonstrates consistent mean fluorescent intensity across across passage10-26. (A) Human IL7Rα expression analysis. (B) Human TSLPR expression analysis.
Protocol
Passage stability analysis by Signaling Bioassay. The continuously growing TSLPR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TSLP protein. Human TSLP protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-26.
Protocol
Inhibition of human TSLP protein-induced reporter activity by anti-human TSLP neutralizing antibody. This reporter cell was incubated with serial dilutions of antibodies in the presence of human TSLP protein (AcroBiosystems, Cat.No.TSP-H52Hb) with a final concentration of 0.3 μg/mL. The EC50 of anti-human TSLP neutralizing antibody is approximately 0.55 μg/mL.
Protocol
Expression analysis of human EGFR on EGFR (Luc) HEK293 Reporter Cell by FACS. Cell surface staining was performed on EGFR (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-EGFR antibody.
Protocol
Response to human EGF protein (RLU). The EGFR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human EGF protein (AcroBiosystems, Cat.No.EGF-H52H3). The EC50 was approximately 56.23 ng/mL.
Protocol
Response to human EGF protein (Fold). The EGFR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human EGF protein (AcroBiosystems, Cat.No.EGF-H52H3). The max induction fold was approximately 56.
Protocol
Passage stability analysis of receptor expression by FACS. Flow cytometry surface staining of human EGFR on EGFR (Luc) HEK293 Reporter Cell demonstrates consistent mean fluorescent intensity across across passage10-20.
Protocol
Passage stability analysis by Signaling Bioassay. The continuously growing EGFR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human EGF protein. Human EGF protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-20.
Protocol
Inhibition of human EGF protein-induced reporter activity by anti-human EGFR neutralizing antibody. This reporter cell was incubated with serial dilutions of antibodies in the presence of human EGF protein (AcroBiosystems, Cat.No.EGF-H52H3) with a final concentration of 50 ng/mL. The EC50 of anti-human EGFR neutralizing antibody (Cetuximab) is approximately 1.793 μg/mL.
Protocol
Inhibition of human EGF protein-induced reporter activity by human EGFR small molecule inhibitor. This reporter cell was incubated with serial dilutions of inhibitors in the presence of human EGF protein (AcroBiosystems, Cat.No.EGF-H52H3) with a final concentration of 50 ng/mL. The EC50 of human EGFR small molecule inhibitor (Erlotinib) was approximately 0.01 μM.
Protocol
Expression analysis of human VEGFR2 on VEGFR2 (Luc) HEK293 Reporter Cell by FACS. Cell surface staining was performed on VEGFR2 (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-VEGFR2 antibody
Protocol
Response to human VEGF165 protein (RLU). The VEGFR2 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human VEGF165 protein (AcroBiosystems, Cat.NO.VE5-H4210). The EC50 was approximately 5.13 ng/mL.
Protocol
Response to human VEGF165 protein (Fold). The VEGFR2 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human VEGF165 protein (AcroBiosystems, Cat.NO.VE5-H4210). The max induction fold was approximately 70.
Protocol
Passage stability analysis of receptor expression by FACS. Flow cytometry surface staining of human VEGFR2 on VEGFR2 (Luc) HEK293 Reporter Cell demonstrates consistent mean fluorescent intensity across passage10-32.
Protocol
Passage stability analysis by Signaling Bioassay. The continuously growing VEGFR2 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human VEGF165 protein. Human VEGF165 protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-32.
Protocol
Inhibition of human VEGF165 protein-induced reporter activity by anti-human VEGF neutralizing antibody. This reporter cell was incubated with serial dilutions of antibodies in the presence of human VEGF165 protein (AcroBiosystems, Cat.NO.VE5-H4210) with a final concentration of 10 ng/mL. The EC50 of anti-human VEGF neutralizing antibody (Bavacizumab) is approximately 0.0071 μg/mL.
Protocol
Inhibition of human VEGF165 protein-induced reporter activity by human VEGFR2 small molecule inhibitor. This reporter cell was incubated with serial dilutions of inhibitors in the presence of human VEGF165 protein (AcroBiosystems, Cat.NO.VE5-H4210) with a final concentration of 10 ng/mL. The EC50 of human VEGFR2 small molecule inhibitor (Cabozantinib) was approximately 0.0053 μM.
Protocol
